Validating the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models

During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost discussed with Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, about the latest updates from the PRISM platform towards obtaining high-resolution profiling of microbial communities both at the taxonomic and the functional levels and the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.